Opioids in chronic noncancer pain—are opioids different?: A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids of at least four week’s duration;Opioide bei chronischen nicht-tumorbedingten Schmerzen – gibt es Unterschiede?: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten Direktvergleichen von Opioiden über mindestens 4 Wochen

Schmerz

Volumn 29, Issue 1, 2015, Pages 73-84

  Lauche, R ^a   Klose, P ^a   Radbruch, L ^b   Welsch, P ^c   Hauser W ^d,e  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Stichting Rugzorg Nederland   (Netherlands)

^d KLINIKUM SAARBRÜCKEN   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adverse events; Meta analysis; Opioids; Oral administration; Transdermal administration

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE DERIVATIVE; OXYCODONE; OXYMORPHONE; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ARTICLE; ATTRIBUTABLE RISK; CANCER PAIN; CHRONIC NONCANCER PAIN; CHRONIC PAIN; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCOPUS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; CUTANEOUS DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; LONG TERM CARE; MEASUREMENT ACCURACY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; CHRONIC PAIN; DATA ACCURACY; EVIDENCE-BASED MEDICINE; HUMANS; LONG-TERM CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925485105     PISSN: 0932433X     EISSN: 14322129     Source Type: Journal    
DOI: 10.1007/s00482-014-1432-4     Document Type: Article

References (44)

1. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
2. Chaparro LE, Furlan AD, Deshpande A et al (2013) Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 8:CD004959
3. Chou R, Carson S (2008) Drug class review on long-acting opioid analgesics: final report update 5 [Internet]. Oregon Health & Science University, Portland. http://www.ncbi.nlm.nih.gov/books/NBK10648/. Zugegriffen: 16. Dezember 2013
4. Chou R (2010) What we still don’t know about treating chronic noncancer pain with opioids. CMAJ 182:881–882
5. D’Agostino RB Sr, Massaro JM, Sullivan LM (2003) Non-inferiority trials: design concepts and issues—the encounters of academic consultants in statistics. Stat Med 22:169–186
6. Egger M, Smith GD, Schneider M (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
7. Gammaitoni AR, Fine P, Alvarez N et al (2003) Clinical application of opioid equianalgesic data. Clin J Pain 19:286–297
8. Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394
9. Häuser W, Bartram-Wunn E, Bartram C et al (2011) Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain 152:1709–1717
10. Higgins JPT, Green S (o J) Cochrane Handbook for systematic reviews of intervention. Version 5.1.0. http://handbook.cochrane.org/
11. Höer A, Kurepkat M, Gottberg A, Häussler B (2008) Transdermal and oral opioids for outpatient pain therapy. Comparing patients‘ characteristics by a claims data analysis. Schmerz 22:156–163
12. Itz CJ, Geurts JW, Kleef M van, Nelemans P (2013) Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain 17:5–15
13. Kissin I (2013) Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety? J Pain Res 6:513–529
14. Manchikanti L, Vallejo R, Manchikanti KN et al (2011) Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 14:E133–E156
15. Merker M, Dinges G, Koch T et al (2012) Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies. Schmerz 26:16–26
16. Miller K, Yarlas A, Wen W et al (2013) Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opin Pharmacother 14:269–77
17. Mitra F, Chowdhury S, Shelley M, Williams G (2013). A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Pain Med14:75–83
18. Moher D, Liberati A, Teztlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 51:1–7
19. Moore RA, Eccleston C, Derry S et al (2010) „Evidence“ in chronic pain—establishing best practice in the reporting of systematic reviews. Pain 150:386–389
20. Nüesch E, Rutjes AW, Husni E et al (2009) Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 4:CD003115
21. Pillastrini P, Gardenghi I, Bonetti F et al (2012) An updated overview of clinical guidelines for chronic low back pain management in primary care. Joint Bone Spine 79:176–185
22. Reinecke H, Sorgatz H, German Society for the Study of Pain (DGSS) (2009) S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz 23:440–447
23. Review Manager (RevMan) [Computerprogramm]. Version 5.2. The Nordic Cochrane Centre, The Cochrane Collaboration, Kopenhagen, 2012
24. Rigler SK, Shireman TI, Kallenbach L (2007) Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries. Am J Geriatr Pharmacother 5:91–99
25. Schaefert R, Welsch P, Petzke F et al (2014) Opioide bei chronischem Arthroseschmerz. Systematische Übersicht und Metaanalyse der Wirksamkeit und Risiken in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1451-1
26. Schubert I, Ihle P, Sabatowski R (2013) Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Dtsch Arztebl Int 110:45–51
27. Von Korff M, Kolodny A, Deyo RA, Chou R (2011) Long-term opioid therapy reconsidered. Ann Intern Med 55:325–328
28. Washington State Agency Medical Directors‘ Group. Opioid dose calculator. http://agencymeddirectors.wa.gov/mobile.html. Zugegriffen: 10. Januar 2014
29. Wolff RF, Aune D, Truyers C et al (2012) Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin 28:833–845
30. Afilalo M, Etropolski MS, Kuperwasser B et al (2010) Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 30:489–505
31. Afilalo M, Morlion B (2013) Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 16:27–40
32. Allan L, Hays H, Jensen NH et al (2001) Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322:1154–1158
33. Allan L, Richarz U, Simpson K, Slappendel R (2005) Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine (Phila Pa 1976) 30:2484–2490
34. Binsfeld H, Szczepanski L, Waechter S et al (2010) A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 10:404–415
35. Buynak R, Shapiro DY, Okamoto A et al (2010) Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 11:1787–1804
36. Hale ME, Tudor IC, Khanna S, Thipphawong J (2007) Efficacy and tolerability of once daily OROS hydromorphone and twice daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 29:874–888
37. Hale ME, Upmalis D, Okamoto A et al (2009) Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 25:1095–1104
38. Karlsson M, Berggren AC (2009) Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther 31:503–513
39. Matsumoto AK, Babul N, Ahdieh H (2005) Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 6:357–366
40. Nicholson B, Ross E, Sasaki J, Weil A (2006) Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 22:1503–1514
41. Rauck RL, Bookbinder SA, Bunker TR et al (2006) The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended- release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2:155–166 (Erratum in: J Opioid Manag 2006; 2:276)
42. Wild JE, Grond S, Kuperwasser B et al (2010) Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 10:416–427
43. Mercier F, Claret L, Prins K, Bruno R (2014) A model-based meta-analysis to compare efficacy and tolerability of tramadol and tapentadol for the treatment of chronic non-malignant pain. Pain Ther 3(1):31–44
44. Riemsma R, Forbes C, Harker J et al (2011) Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 27(10):1907–1930